MARKET

GYRE

GYRE

Gyre Therapeutics Inc
NASDAQ
6.61
-0.07
-1.05%
Opening 10:21 08/28 EDT
OPEN
6.70
PREV CLOSE
6.68
HIGH
6.70
LOW
6.56
VOLUME
6.45K
TURNOVER
--
52 WEEK HIGH
9.42
52 WEEK LOW
5.44
MARKET CAP
737.08M
P/E (TTM)
-33.8801
1D
5D
1M
3M
1Y
5Y
1D
Gyre Therapeutics unveils capital-efficient global development strategy
TipRanks · 2d ago
Weekly Report: what happened at GYRE last week (0817-0821)?
Weekly Report · 4d ago
Weekly Report: what happened at GYRE last week (0810-0814)?
Weekly Report · 08/17 09:10
Analysts Are Bullish on These Healthcare Stocks: Gyre Therapeutics (GYRE), Align Tech (ALGN)
TipRanks · 08/10 13:20
Weekly Report: what happened at GYRE last week (0803-0807)?
Weekly Report · 08/10 09:09
Gyre Q2 Loss Widens As Revenue Edges Lower; Reaffirms Revenue Guidance
NASDAQ · 08/10 07:37
Thin Float, Heavy Overhang: Analyst Warns Gyre Therapeutics’ Concentrated Ownership and Pledged Shares Heighten Liquidity and Control Risks
TipRanks · 08/10 06:01
H.C. Wainwright Sticks to Its Buy Rating for Gyre Therapeutics (GYRE)
TipRanks · 08/07 15:35
More
About GYRE
Gyre Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. It is also advancing a diverse pipeline in the PRC through its controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, and F528. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. It is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. It is also focused on commercializing the avatrombopag product and discovery and development of targeted protein degrader and degrader antibody conjugate therapies.

Webull offers Gyre Therapeutics Inc stock information, including NASDAQ: GYRE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GYRE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GYRE stock methods without spending real money on the virtual paper trading platform.